(Q37402645)

20 August 2017

1 reference

title

Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: incidence, risk factors and therapeutic options (English)

1 reference

20 August 2017

0 references

4

Fabio Ciceri

1 reference

20 August 2017

Andrés J M Ferreri

1

1 reference

PubMed ID

19247977

20 August 2017

Andrea Assanelli

series ordinal

2

1 reference

PubMed ID

19247977

20 August 2017

Roberto Crocchiolo

series ordinal

3

1 reference

20 August 2017

1 June 2009

1 reference

20 August 2017

Hematological Oncology

1 reference

20 August 2017

27

1 reference

20 August 2017

2

1 reference

20 August 2017

61-70

1 reference

Meningeal localization in a patient with Hodgkin's disease. Description of a case and review of the literature

20 August 2017

1 reference

CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes.

21 January 2018

1 reference

Malignant cells in cerebrospinal fluid (CSF): The meaning of a positive CSF cytology

21 January 2018

1 reference

Central nervous system relapse in non-Hodgkin lymphoma. A single-center study of 532 patients.

21 January 2018

1 reference

Graft-versus-lymphoma effect after allogeneic peripheral blood stem cell transplantation for primary central nervous system lymphoma.

21 January 2018

1 reference

Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report

21 January 2018

1 reference

7 January 2021

Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lympho

1 reference

7 January 2021

Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

1 reference

7 January 2021

Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model

1 reference

7 January 2021

Central nervous system involvement in indolent lymphomas

1 reference

7 January 2021

1 reference

7 January 2021

Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions

1 reference

7 January 2021

Central nervous system involvement in mantle cell lymphoma

1 reference

7 January 2021

Involvement of the central nervous system by non-Hodgkin's lymphoma: the Southwest Oncology Group experience

1 reference

7 January 2021

Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience

1 reference

7 January 2021

Central nervous system relapse of systemic non-Hodgkin's lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy

1 reference

7 January 2021

Central nervous system relapse in unfavourable-histology non-Hodgkin's lymphoma: is prophylaxis indicated?

1 reference

7 January 2021

Central nervous system involvement in non-Hodgkin's lymphoma: an analysis of 105 cases

1 reference

7 January 2021

Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD)

1 reference

7 January 2021

Analysis of immunoglobulin and T cell receptor genes. Part I: Basic and technical aspects

1 reference

7 January 2021

Characteristic features of malignant lymphoma with central nervous system involvement

1 reference

7 January 2021

Central nervous system involvement in adult T-cell leukemia/lymphoma

1 reference

7 January 2021

High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology

1 reference

7 January 2021

Central nervous system prophylaxis with combined intravenous and intrathecal methotrexate in diffuse lymphoma of aggressive histologic type

1 reference

7 January 2021

CNS involvement in mantle-cell lymphoma.

1 reference

7 January 2021

Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab.

1 reference

7 January 2021

Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up

1 reference

7 January 2021

Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.

1 reference

7 January 2021

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

1 reference

7 January 2021

For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory? Dutch HOVON Group.

1 reference

7 January 2021

Central nervous system metastases from non-Hodgkin's lymphoma: treatment and prophylaxis.

1 reference

7 January 2021

Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis

1 reference

7 January 2021

Effect of dose and repeat intravenous 24 hr infusions of methotrexate on cerebrospinal fluid availability in children with hematological malignancies

1 reference

7 January 2021

CSF drug levels for children with acute lymphoblastic leukemia treated by 5 g/m2 methotrexate. A study from the EORTC Children's Leukemia Cooperative Group

1 reference

7 January 2021

Cerebrospinal fluid drug levels of leukemic children receiving intravenous 5 g/m2 methotrexate.

1 reference

7 January 2021

MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas

1 reference

7 January 2021

Extended CSF cytarabine exposure following intrathecal administration of DTC 101.

1 reference

7 January 2021

Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis.

1 reference

7 January 2021

Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment

1 reference

7 January 2021

Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma

1 reference

7 January 2021

Autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma and CNS involvement: those transplanted with active CNS disease have a poor outcome--a report by the European Bone Marrow Transplant Lymphoma Registry

1 reference

7 January 2021

High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma

1 reference

7 January 2021

Central nervous system relapse of lymphoid malignancies in adults: the role of high-dose chemotherapy

1 reference

7 January 2021

Pharmacology of agents used in bone marrow transplant conditioning regimens

1 reference

7 January 2021

Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis

1 reference

7 January 2021

Combined immunoradiotherapy induces long-term remission of CNS relapse of peripheral, diffuse, large-cell lymphoma after allogeneic stem cell transplantation: case study

1 reference

7 January 2021

Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10.

1 reference

7 January 2021

Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma

1 reference

7 January 2021

[Treatment of primary central nervous system lymphoma in the immunocompetent patient]

1 reference

7 January 2021

Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: long term results of the EORTC CLG 58881 trial

1 reference

7 January 2021

Cause-specific mortality and second cancer incidence after non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study

1 reference

7 January 2021

Identifiers

DOI

10.1002/HON.881

1 reference

20 August 2017

1 reference

PubMed ID

19247977